Year-end Sale % OFF 
Abstract
Abstract In the past few years, newer classes of drugs for the treatment of type 2 diabetes mellitus have been discovered and delivered with significant glucose-lowering effect and weight reduction. Among these are glucagon-like peptide-1 receptor agonists (GLP 1 RAs), a class with the most promising results. However, inconvenience with the use of these agents is being the injectable route of administration. To address the problem, a GLP-1 RA, semaglutide, has been developed that can be administered orally with similar effects to that of injectable (subcutaneous) preparation in terms of efficacy and safety. This article tends to focus on the pleiotropic benefits of GLP-1RAs, as a class, in the management of diabetes and beyond.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
